349 related articles for article (PubMed ID: 26094169)
1. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Sharma P; Zargar-Shoshtari K; Caracciolo JT; Fishman M; Poch MA; Pow-Sang J; Sexton WJ; Spiess PE
Urol Oncol; 2015 Aug; 33(8):339.e17-23. PubMed ID: 26094169
[TBL] [Abstract][Full Text] [Related]
2. Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.
Fukushima H; Nakanishi Y; Kataoka M; Tobisu KI; Koga F
Clin Genitourin Cancer; 2017 Apr; 15(2):e229-e238. PubMed ID: 27601279
[TBL] [Abstract][Full Text] [Related]
3. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Khan AI; Psutka SP; Patil DH; Hong G; Williams MA; Bilen MA; Sekhar A; Kissick HT; Narayan VM; Joshi SS; Ogan K; Master VA
Cancer; 2022 Jun; 128(11):2073-2084. PubMed ID: 35285950
[TBL] [Abstract][Full Text] [Related]
6. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy.
Corcoran AT; Kaffenberger SD; Clark PE; Walton J; Handorf E; Piotrowski Z; Tomaszewski JJ; Ginzburg S; Mehrazin R; Plimack E; Chen DY; Smaldone MC; Uzzo RG; Morgan TM; Kutikov A
BJU Int; 2015 Sep; 116(3):351-7. PubMed ID: 25123843
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Sarcopenia in Patients with Metastatic Renal Cell Carcinoma.
Fukushima H; Nakanishi Y; Kataoka M; Tobisu K; Koga F
J Urol; 2016 Jan; 195(1):26-32. PubMed ID: 26292042
[TBL] [Abstract][Full Text] [Related]
9. Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer.
Psutka SP; Boorjian SA; Moynagh MR; Schmit GD; Costello BA; Thompson RH; Stewart-Merrill SB; Lohse CM; Cheville JC; Leibovich BC; Tollefson MK
J Urol; 2016 Feb; 195(2):270-6. PubMed ID: 26292038
[TBL] [Abstract][Full Text] [Related]
10. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?
Culp SH; Tannir NM; Abel EJ; Margulis V; Tamboli P; Matin SF; Wood CG
Cancer; 2010 Jul; 116(14):3378-88. PubMed ID: 20564061
[TBL] [Abstract][Full Text] [Related]
11. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
[TBL] [Abstract][Full Text] [Related]
13. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy.
Spiess PE; Kurian T; Lin HY; Rawal B; Kim T; Sexton WJ; Pow-Sang JM
BJU Int; 2012 Dec; 110(11 Pt B):E470-4. PubMed ID: 22519938
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
[TBL] [Abstract][Full Text] [Related]
15. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
18. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y
Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986
[TBL] [Abstract][Full Text] [Related]
19. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
[TBL] [Abstract][Full Text] [Related]
20. Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus.
Watanabe S; Ishihara H; Takagi T; Kondo T; Ishiyama R; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(5):819-825. PubMed ID: 33558883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
